Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1

First Page		Document Content
Date: 2015-01-27 15:09:34 Shionogi Menopause Dyspareunia Estrogen Vaginal lubrication Human reproduction Endocrine system Reproductive system		Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1 Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 50,94 KB Share Document on Facebook